<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343472</url>
  </required_header>
  <id_info>
    <org_study_id>SPP0311F08</org_study_id>
    <nct_id>NCT01343472</nct_id>
  </id_info>
  <brief_title>Evaluation of the Washington Intensive Supervision Program</brief_title>
  <official_title>Evaluation of the Washington Intensive Supervision Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pepperdine University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pepperdine University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study entails an evaluation of the Washington Intensive Supervision Program (WISP). The
      purpose of the evaluation is to test whether subjects assigned to WISP perform better than
      those assigned to parole-as-usual (PAU).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study entails an evaluation of the Washington Intensive Supervision Program (WISP). WISP
      is a program targeting high-risk parolees in Seattle, and is modeled after the HOPE program
      in Hawaii. The purpose of the evaluation is to test whether subjects assigned to WISP perform
      better than those assigned to parole-as-usual (PAU) on a number of outcomes, including drug
      use, missed appointments, recidivism, prison and jail stays, and parole revocations. WISP
      uses regular random drug testing and close community supervision, paired with swift and
      certain, but modest sanctions for every detected violation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revocation rate</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects in each condition who are revoked from parole and returned to prison</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% positive drug tests</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of random and scheduled drug tests that test positive for illicit drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days incarcerated</measure>
    <time_frame>12 months</time_frame>
    <description>Total number of days incarcerated in jail or prison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Missed appointments</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of parole appointments that are missed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New arrests</measure>
    <time_frame>12 months</time_frame>
    <description>Number of new arrests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessed risk</measure>
    <time_frame>12 months</time_frame>
    <description>Parolee risk assessment (high, medium, low)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Behavior</condition>
  <condition>Drug Users</condition>
  <arm_group>
    <arm_group_label>WISP supervision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parolee supervised under WISP parole model.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parole-as-usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parolees supervised under Washington State's parole-as-usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>WISP supervision</intervention_name>
    <description>WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.</description>
    <arm_group_label>WISP supervision</arm_group_label>
    <other_name>HOPE supervision</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Parole-as-usual</intervention_name>
    <description>Parolees are supervised under standard parole supervision practice in Washington State.</description>
    <arm_group_label>Parole-as-usual</arm_group_label>
    <other_name>PAU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inmates released by DOC to community corrections supervision

          -  Supervised out of the Seattle CJC (Community Justice Center) to include field offices
             and offenders from the downtown &quot;Metro&quot; unit, Southeast Seattle unit, Northgate (north
             Seattle) and West Seattle.

          -  Have a parole supervision discharge date at least one year from the date of release
             from entry into WISP

        Exclusion Criteria:

          -  Level III Sex Offenders

          -  Existing assignment to supervision that precludes WISP. These include: Drug Offender
             Sentencing Alternative (DOSA)and Special Sex Offender Sentencing Alternative (SSOSA).

          -  Dangerously Mentally Ill (DMIO)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Hawken, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pepperdine University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Community Justice Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pepperdine University</investigator_affiliation>
    <investigator_full_name>Brett T. Leach</investigator_full_name>
    <investigator_title>Regulatory Affairs Specialist</investigator_title>
  </responsible_party>
  <keyword>Behavior</keyword>
  <keyword>Drug users</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

